Media ReleasesCircadian

View All Circadian News


VGX-100 identified as potential new therapy for Dry Eye Disease

Melbourne, Australia September 13, 2011– Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) announced today the publication of data in the scientific journal Archives of Ophthalmology showing that its lead development molecule VGX-100, a human antibody against the angiogenic and lymphangiogenic molecule VEGF-C, can significantly reduce inflammation and corneal tissue damage associated with Dry Eye Disease (DED). The data indicates a major new therapeutic  opportunity for VGX-100 in the DED setting.


For further information please download PDF below:

Download this document